Tyra Biosciences, Inc.

Report azionario NasdaqGS:TYRA

Capitalizzazione di mercato: US$1.5b

Tyra Biosciences Gestione

Criteri Gestione verificati 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Todd Harris

Amministratore delegato

US$5.6m

Compenso totale

Percentuale dello stipendio del CEO11.82%
Mandato del CEO8yrs
Proprietà del CEO2.3%
Durata media del management4.2yrs
Durata media del Consiglio di amministrazione5.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Aug 10

Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet

Summary TYRA's dabogratinib has an upcoming readout in September 2026 that I think could validate its FGFR3 profile. However, if they succeed with that trial, I believe it would also help TYRA's broader SNAP drug-design platform. In that sense, a strong, complete-response signal with a good safety profile could de-risk dabogratinib and improve TYRA's risk-reward profile as a whole. Aside from SURF302, TYRA also has other interesting pipeline catalysts with SURF303 and BEACH301 planned for 2027. Plus, TYRA appears funded through those clinical catalysts, so I believe the stock is a viable speculative "Buy" at these levels. Read the full article on Seeking Alpha
Articolo di analisi • Oct 01

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Mar 28

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 01

Tyra Biosciences: FGFR1/2 Driven AE Data Spooked The Market

Summary Tyra Biosciences' TYRA-300, an oral FGFR3 inhibitor, showed promising efficacy but raised concerns with some FGFR1/2-driven adverse events, causing a significant stock drop. TYRA-300 demonstrated better safety and tolerability compared to erdafitinib, with fewer high-grade toxicities and lower incidence of hyperphosphatemia and other side effects. Financially, Tyra has a market cap of $632mn, a cash balance of $360mn, and a cash runway of 11–20 quarters, depending on expenses. The market's reaction to TYRA-300's data was mixed; further data from the SURF301 trial is needed to make a definitive investment decision. Read the full article on Seeking Alpha
Seeking Alpha • Dec 17

The Take On Tyra Biosciences

Summary Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg. TYRA-300 aims to overcome limitations of existing mUC therapies like Balversa, with ongoing trials at higher 120mg doses and other cancer/genetic indications. Despite safety concerns, analysts remain bullish on Tyra, with unanimous Buy ratings and price targets between $28 and $33 per share. RA Capital Management increased its stake in Tyra, signaling confidence, but the path to first-line therapy approval remains uncertain pending further data. An analysis around Tyra Biosciences follows in the paragraphs below. Read the full article on Seeking Alpha
Articolo di analisi • Dec 11

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Oct 21

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Key Insights Tyra Biosciences' estimated fair value is US$25.61 based on 2 Stage Free Cash Flow to Equity Tyra...
Seeking Alpha • Oct 21

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Summary Tyra Biosciences will release interim data for its FGFR3-inhibitor TYRA-300 in treating urothelial carcinoma and solid tumors at ENA 2024 on October 25th. Positive interim data could advance TYRA-300 towards a phase 2 study for metastatic urothelial carcinoma and non-muscle invasive bladder cancer patients. TYRA-300 also shows potential for treating skeletal dysplasia disorders, with an IND filing for achondroplasia expected in the second half of 2024. TYRA has a strong cash position, with $373.8 million as of June 30, 2024, sufficient to fund operations into 2026. Read the full article on Seeking Alpha
Articolo di analisi • Aug 29

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 23

Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences

Summary Tyra Biosciences, Inc. has no revenue or earnings, but share prices have increased by 32.68% in the past year. The company focuses on precision medicines targeting FGFR biology, with future promise in oncology and genetic conditions. Despite bullish signals, the lack of key fundamentals makes Tyra a speculative play, rated as a Hold with potential for growth. Read the full article on Seeking Alpha
Articolo di analisi • Jul 05

A Look At The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Key Insights The projected fair value for Tyra Biosciences is US$18.25 based on 2 Stage Free Cash Flow to Equity Tyra...
Articolo di analisi • May 13

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Articolo di analisi • Jan 13

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Sep 27

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Jun 13

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Tyra Biosciences...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Todd Harris rispetto agli utili di Tyra Biosciences?
DataCompenso totaleStipendioUtili della società
Jun 30 2026n/an/a

-US$149m

Mar 31 2026n/an/a

-US$131m

Dec 31 2025US$6mUS$658k

-US$120m

Sep 30 2025n/an/a

-US$112m

Jun 30 2025n/an/a

-US$106m

Mar 31 2025n/an/a

-US$96m

Dec 31 2024US$8mUS$633k

-US$86m

Sep 30 2024n/an/a

-US$84m

Jun 30 2024n/an/a

-US$81m

Mar 31 2024n/an/a

-US$75m

Dec 31 2023US$5mUS$608k

-US$69m

Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$51m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$2mUS$581k

-US$55m

Sep 30 2022n/an/a

-US$52m

Jun 30 2022n/an/a

-US$46m

Mar 31 2022n/an/a

-US$37m

Dec 31 2021US$6mUS$443k

-US$26m

Sep 30 2021n/an/a

-US$20m

Jun 30 2021n/an/a

-US$16m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$1mUS$350k

-US$9m

Compensazione vs Mercato: La retribuzione totale di Todd ($USD 5.57M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 5.10M ).

Compensazione vs guadagni: La retribuzione di Todd è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Todd Harris (47 yo)

8yrs
Mandato
US$5,566,997
Compensazione

Dr. Todd Harris, Ph D., co-founded Tyra Biosciences, Inc. and serves as President and Chief Executive Officer since November 2018 and Director since August 2018 and had been its Secretary November 2018 and...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Todd Harris
Co-Founder8yrsUS$5.57m2.28%
$ 34.4m
Bhavesh Ashar
Chief Operating Officerless than a yearUS$5.19mNessun dato
Douglas Warner
Chief Medical Officer1.9yrsUS$2.37m0%
$ 0
Daniel Bensen
Co-Founder & Chief Discovery Officer8yrsUS$2.66m0.25%
$ 3.7m
Alan Fuhrman
Chief Financial Officer3.6yrsUS$3.53m0.027%
$ 408.9k
Julia Rueb
VP of Finance & Principal Accounting Officerless than a yearNessun dato0.073%
$ 1.1m
Robert Hudkins
Chief Technology Officer5.6yrsNessun datoNessun dato
Ronald Swanson
Chief Scientific Officer6.6yrsUS$2.53mNessun dato
Ali Fawaz
General Counsel & Secretary4.3yrsUS$2.76mNessun dato
Sarah Honig
Senior VP of Corporate Development & Strategy4.1yrsNessun datoNessun dato
Liz Pagano
Chief Human Resources Officer2.2yrsNessun datoNessun dato
Piyush Patel
Chief Development Officer5.6yrsNessun datoNessun dato
4.2yrs
Durata media
57yo
Età media

Gestione esperta: Il team dirigenziale di TYRA è considerato esperto (durata media dell'incarico 4.2 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Todd Harris
Co-Founder8yrsUS$5.57m2.28%
$ 34.4m
Robert J. More
Independent Director7.8yrsUS$232.67k0%
$ 0
Peter Smith
Scientific Advisorno dataNessun datoNessun dato
William Hahn
Scientific Advisorno dataNessun datoNessun dato
Adele M. Gulfo
Independent Director1.6yrsUS$553.72k0.0067%
$ 101.1k
Jeffrey Hager
Scientific Advisorno dataNessun datoNessun dato
Rehan Verjee
Independent Director5.2yrsUS$205.57k0%
$ 0
S. Rothenberg
Independent Director2.3yrsUS$192.47k0%
$ 0
Melissa McCracken
Independent Director5.4yrsNessun datoNessun dato
Jake Simson
Independent Director6.6yrsUS$203.54k0%
$ 0
Susan Moran
Independent Director2.3yrsUS$203.27k0%
$ 0
Jason Sheltzer
Scientific Advisorno dataNessun datoNessun dato
5.3yrs
Durata media
56yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TYRA sono considerati esperti (durata media dell'incarico 5.3 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/08/16 00:51
Prezzo dell'azione a fine giornata2026/08/14 00:00
Utili2026/06/30
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Tyra Biosciences, Inc. è coperta da 19 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Eliana MerleBarclays
Jason ZemanskyBofA Global Research
John NewmanCanaccord Genuity